New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 23, 2014
07:52 EDTISIS, CLDN, ARWR, SRPT, INO, BMRN, ALNY, SGMO, IDRA, BLUE, AGTCPiper Jaffray to hold a symposium
GenomeRX Symposium to be held in New York on June 23.
News For AGTC;ALNY;ARWR;BLUE;BMRN;CLDN;IDRA;INO;ISIS;SGMO;SRPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
November 13, 2014
07:02 EDTAGTCApplied Genetic price target raised to $28 from $24 at Cantor
Subscribe for More Information
05:34 EDTISISAstraZeneca, Isis Pharmaceuticals to co-develop oligonucleotide delivery methods
Subscribe for More Information
November 12, 2014
17:20 EDTSRPTSarepta doses first patient in study of muscular dystrophy candidate Eteplirsen
Subscribe for More Information
16:14 EDTAGTCApplied Genetic reports Q1 EPS (34c), consensus (29c)
Reports Q1 revenue $705K, consensus $270K.
07:53 EDTISIS, BMRNLeerink to hold a tour
Subscribe for More Information
07:08 EDTBLUEbluebird bio reports Q3 EPS (61c), consensus (50c)
Reports Q3 revenue $6.37M, consensus $6.21M.
06:04 EDTCLDNCelladon reports Q3 net loss ($8.4M) vs ($5.5M) in prior period
Subscribe for More Information
November 11, 2014
08:03 EDTALNYAlnylam adds ALN-HDV, ALN-PDL to hepatic infectious disease pipeline
Subscribe for More Information
November 10, 2014
16:07 EDTISISIsis Pharmaceuticals files to sell $425M in convertible senior notes due 2021
Subscribe for More Information
10:04 EDTBMRNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:18 EDTARWRArrowhead announces presentation of ongoing Phase 2a ARC-520 data
Subscribe for More Information
07:08 EDTBLUEbluebird bio names James DeTore as CFO, treasurer
Subscribe for More Information
06:02 EDTBMRNBioMarin upgraded to Buy from Neutral at Goldman
Goldman upgraded BioMarin to Buy based on increased confidence in BMN-111 for achondroplasia with expected proof-of-concept data in Q2 2015. The firm now sees a greater than 50% probability of success and peak sales of $900M. Price target raised to $104 from $78.
06:02 EDTINOInovio reports Q3 EPS (12c), consensus (14c)
Subscribe for More Information
November 9, 2014
14:09 EDTALNYAlnylam management to meet with Needham
Subscribe for More Information
November 7, 2014
20:27 EDTALNYAlnylam management to meet with Piper Jaffray
Meeting to be held in New York on November 12 hosted by Piper Jaffray.
08:33 EDTISISIsis Pharmaceuticals reports Q3 EPS (23c), consensus (20c)
Subscribe for More Information
07:55 EDTSGMOSangamo management to meet with Piper Jaffray
Subscribe for More Information
07:19 EDTIDRAIdera Pharmaceuticals to expand rare disease development portfolio
Idera Pharmaceuticals announced plans to collaborate with Parent Project Muscular Dystrophy, or PPMD, to develop a potential non-steroid-based anti-inflammatory treatment using Idera's Toll-like receptor, or TLR, antagonism technology. DMD is a rare, fatal muscle disorder affecting approximately 15,000-20,000 patients in the U.S. It is characterized by progressive muscle weakness, pulmonary and cardiac dysfunction, and death typically before age 30. Previously published independent research has shown that TLR 7 is up-regulated in DMD patients.1 In a preclinical model of DMD, knockout of the gene for the MYD88 TLR adaptor protein led to significant improvements in skeletal and cardiac muscle function. In a separate study conducted by researchers from Children's National Health System and Idera, treatment with a TLR antagonist candidate led to a significant reduction of pro-inflammatory cytokines, a significant decrease in creatine kinase, and a significant increase in muscle strength in a preclinical DMD model.2 Idera plans to collaborate with PPMD to expand preclinical studies and develop a clinical development strategy for a TLR antagonist candidate in DMD.
07:15 EDTIDRAIdera Pharmaceuticals reports Q3 EPS (11c), consensus (11c)
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use